United Arab Emirates
Key Insights
- 1
No psychedelic therapies are publicly approved in the UAE; access is limited to tightly controlled medical use, with narcotics and psychotropics still criminalised outside authorised channels.
- 2
The database shows 1 trial, 0 active, and 2 compounds studied: esketamine and placebo, making the country’s clinical footprint extremely thin.
- 3
UAE investigators published a real-world intranasal esketamine study in 2026, one of the first local clinical datasets on treatment-resistant depression.
- 4
Momentum now hinges on the UAE’s 2025–26 regulatory tightening around medical products and research licensing, which could either enable or further constrain psychotropic studies.
Reimbursed Care Access
The United Arab Emirates maintains strict national controls on classic recreational psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, ibogaine, ayahuasca, 5‑MeO‑DMT), which are effectively prohibited outside of approved research. At the same time, pharmaceutical derivatives developed for medical use — notably esketamine (Spravato) — have been licensed/introduced into UAE clinical settings under Ministry of Health supervision, but access is typically limited to specialist clinics/private hospitals and reimbursement is uncommon or highly restricted. Ketamine is an approved anesthetic and is legally supplied for medical uses under prescription, but psychiatric (off‑label) ketamine infusion programs are generally delivered in private settings with limited public insurance reimbursement and variable prior‑authorization requirements.
Quick Indicators
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in United Arab Emirates.